论文部分内容阅读
目的探讨乳腺癌组织中AP-2、Cerb B-2的表达与相关性及其临床意义。方法采用免疫组织化学方法检测91例乳腺癌中AP-2、Cerb B-2的表达,其中导管原位癌27例,浸润性导管癌64例。结果 AP-2和Cerb B-2在乳腺癌不同分级中的表达差异均有统计学意义(P<0.05),且随着组织学分级的增高表达越高;AP-2和Cerb B-2的表达与有无淋巴结转移无关;AP-2与Cerb B-2在乳腺癌中的表达呈正相关关系。结论乳腺癌中AP-2、Cerb B-2的表达均与乳腺癌的分级有关,检测这两个指标可以为研究乳腺癌的进展和转移机制及评判其生物学行为提供有价值的参考,同时为乳腺癌的治疗提供一个新的靶点。
Objective To investigate the expression of AP-2 and Cerb B-2 in breast cancer and their clinical significance. Methods The expressions of AP-2 and Cerb B-2 in 91 cases of breast cancer were detected by immunohistochemical staining, including 27 cases of ductal carcinoma in situ and 64 cases of invasive ductal carcinoma. Results The expressions of AP-2 and Cerb B-2 in different grades of breast cancer were significantly different (P <0.05), and were higher with the increase of histological grade. The expression of AP-2 and Cerb B-2 The expression of AP-2 was positively correlated with the expression of Cerb B-2 in breast cancer. Conclusions The expression of AP-2 and Cerb B-2 in breast cancer is related to the grade of breast cancer. Detecting these two indexes can provide valuable reference for studying the mechanism of breast cancer progression and metastasis and judging its biological behavior. Meanwhile, Breast cancer treatment provides a new target.